Effect of UGT Polymorphisms on Pharmacokinetics and Adverse Reactions of Mycophenolic Acid in Kidney Transplant Patients

References

• Dasgupta A . Therapeutic drug monitoring of mycophenolic acid. Adv. Clin. Chem.76, 165–184 (2016).
   PubMed Web of Science ®Google Scholar
• Bentata Y . Mycophenolates: the latest modern and potent immunosuppressive drugs in adult kidney transplantation: what we should know about them?Artif. Organs44(6), 561–576 (2020).
   PubMed Web of Science ®Google Scholar
• Staatz CE , TettSE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch. Toxicol.88(7), 1351–1389 (2014).
   PubMed Web of Science ®Google Scholar
• Bumgardner GL , RobertsJP. New immunosuppressive agents. Gastroenterol. Clin. North Am.22(2), 421–449 (1993).
   PubMed Web of Science ®Google Scholar
• Zhang J , SunZ , ZhuZet al. Pharmacokinetics of mycophenolate mofetil and development of limited sampling strategy in early kidney transplant recipients. Front. Pharmacol.9, 908 (2018).
   PubMed Web of Science ®Google Scholar
• Guo M , WangZJ , YangHWet al. Influence of genetic polymorphisms on mycophenolic acid pharmacokinetics and patient outcomes in renal transplantation. Curr. Drug Metab.19(14), 1199–1205 (2018).
   PubMed Web of Science ®Google Scholar
• Fujiyama N , MiuraM , KatoS , SoneT , IsobeM , SatohS. Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab. Dispos.38(12), 2210–2217 (2010).
   PubMed Web of Science ®Google Scholar
• Staatz CE , TettSE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet.46(1), 13–58 (2007).
   PubMed Web of Science ®Google Scholar
• Kuypers DRJ , MeurYL , CantarovichMet al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephro.5(2), 341–358 (2010).
   PubMed Web of Science ®Google Scholar
• Klotsman M , SathyanG , AndersonWH , GardenOA , ShivanandP. Mycophenolic acid in patients with immune-mediated inflammatory diseases: from humans to dogs. J. Vet. Pharmacol. Ther.42(2), 127–138 (2019).
   PubMed Web of Science ®Google Scholar
• Ling J , ShiJ , JiangQ , JiaoZ. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. Eur. J. Clin. Pharmacol.71(1), 95–106 (2015).
   PubMed Web of Science ®Google Scholar
• Bullingham RE , NichollsA , HaleM. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant. Proc.28(2), 925–929 (1996).
   PubMed Web of Science ®Google Scholar
• Schütz E , ShipkovaM , ArmstrongVW , WielandE , OellerichM. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem.45(3), 419–422 (1999).
   PubMed Web of Science ®Google Scholar
• Wieland E , ShipkovaM , SchellhaasUet al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin. Biochem. 33(2), 107–113 (2000).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , VanrenterghemY , SquiffletJPet al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug Monit.25(5), 609–622 (2003).
   PubMed Web of Science ®Google Scholar
• Meech R , HuDG , McKinnonRAet al. The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms. Physiol. Rev.99(2), 1153–1222 (2019).
   PubMed Web of Science ®Google Scholar
• Picard N , RatanasavanhD , PremaudA , LeMeur Y , MarquetP. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos.33(1), 139–146 (2005).
   PubMed Web of Science ®Google Scholar
• Ramirez J , RatainMJ , InnocentiF. Uridine 5′-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol.6(4), 563–585 (2010).
   PubMed Web of Science ®Google Scholar
• Innocenti F , LiuW , FackenthalDet al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics18(8), 683–697 (2008).
   PubMed Web of Science ®Google Scholar
• Barraclough KA , LeeKJ , StaatzCE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics11(3), 369–390 (2010).
   PubMed Web of Science ®Google Scholar
• Bernard O , GuillemetteC. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos.32(8), 775–778 (2004).
   PubMed Web of Science ®Google Scholar
• Mackenzie PI . Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther. Drug Monit.22(1), 10–13 (2000).
   PubMed Web of Science ®Google Scholar
• Mojarrabi B , MackenziePI. Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem. Biophys. Res. Commun.247(3), 704–709 (1998).
   PubMed Web of Science ®Google Scholar
• Lamba V , SangkuhlK , SanghaviK , FishA , AltmanRB , KleinTE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet. Genomics24(1), 73–79 (2014).
   PubMed Web of Science ®Google Scholar
• Bernard O , TojcicJ , JournaultK , PerusseL , GuillemetteC. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab. Dispos.34(9), 1539–1545 (2006).
   PubMed Web of Science ®Google Scholar
• Basit A , NeradugommaNK , WolfordCet al. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol. Pharm.17(11), 4114–4124 (2020).
   PubMed Web of Science ®Google Scholar
• Mackenzie PI , BockKW , BurchellBet al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics15(10), 677–685 (2005).
   PubMed Web of Science ®Google Scholar
• Miura M , KagayaH , SatohSet al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther. Drug Monit.30(5), 559–564 (2008).
   PubMed Web of Science ®Google Scholar
• Miura M , NiiokaT , KatoSet al. Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. Ther. Drug Monit.33(3), 295–302 (2011).
   PubMed Web of Science ®Google Scholar
• Basu NK , KoleL , KubotaS , OwensIS. Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab. Dispos.32(7), 768–773 (2004).
   PubMed Web of Science ®Google Scholar
• Xie XC , LiJ , WangHYet al. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol. Sin.36(5), 644–650 (2015).
   PubMed Web of Science ®Google Scholar
• Woillard JB , RerolleJP , PicardNet al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br. J. Clin. Pharmacol.69(6), 675–683 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou Z , LuY , SongGet al. In vitro study on influences of UGT1A8 gene polymorphisms on mycophenolate mofetil metabolism. Exp. Clin. Transplant.16(4), 466–472 (2018).
   PubMed Web of Science ®Google Scholar
• Johnson LA , OettingWS , BasuS , PrausaS , MatasA , JacobsonPA. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur. J. Clin. Pharmacol.64(11), 1047–1056 (2008).
   PubMed Web of Science ®Google Scholar
• van Schaik RH , van AgterenM , de FijterJWet al. UGT1A9 -275T >A/-2152C >T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin. Pharmacol. Ther.86(3), 319–327 (2009).
   PubMed Web of Science ®Google Scholar
• Picard N , YeeSW , WoillardJBet al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther.87(1), 100–108 (2010).
   PubMed Web of Science ®Google Scholar
• Vu D , Tellez-CorralesE , YangJet al. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1alpha and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Transpl. Immunol.29(1–4), 155–161 (2013).
   PubMed Web of Science ®Google Scholar
• Kagaya H , InoueK , MiuraMet al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol.63(3), 279–288 (2007).
   PubMed Web of Science ®Google Scholar
• Geng F , JiaoZ , DaoYJet al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin. Chim. Acta413(7–8), 683–690 (2012).
   PubMed Web of Science ®Google Scholar
• Li LQ , ChenDN , LiCJet al. Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients. Pharmacogenomics19(17), 1323–1334 (2018).
   PubMed Web of Science ®Google Scholar
• Woillard JB , PicardN , ThierryA , TouchardG , MarquetP. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet. Genomics24(5), 256–262 (2014).
   PubMed Web of Science ®Google Scholar
• Varnell CD , FukudaT , KirbyCLet al. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs. Pediatr. Transplant.21(7), e13033 (2017).
   Web of Science ®Google Scholar
• Kuypers DR , ClaesK , EvenepoelPet al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol.43(8), 866–880 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao W , FakhouryM , DeschenesGet al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J. Clin. Pharmacol.50(11), 1280–1291 (2010).
   PubMed Web of Science ®Google Scholar
• Betonico GN , Abbud-FilhoM , Goloni-BertolloEMet al. Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients. Transplant. Proc.40(3), 708–710 (2008).
   PubMed Web of Science ®Google Scholar
• Prausa SE , FukudaT , MaseckDet al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin. Pharmacol. Ther.85(5), 495–500 (2009).
   PubMed Web of Science ®Google Scholar
• Boso V , HerreroMJ , BusoEet al. Genotype and allele frequencies of drug-metabolizing enzymes and drug transporter genes affecting immunosuppressants in the Spanish white population. Ther. Drug Monit.36(2), 159–168 (2014).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , NaesensM , VermeireS , VanrenterghemY. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther.78(4), 351–361 (2005).
   PubMed Web of Science ®Google Scholar
• Pazik J , OldakM , LewandowskiZet al. Recipient uridine 5′-diphospho-glucuronosyltransferase UGT1A9 c.98T >C variant determines transplanted kidney filtration rate. Transplant. Proc.46(8), 2678–2682 (2014).
   PubMed Web of Science ®Google Scholar
• Michelon H , KonigJ , DurrbachAet al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics11(12), 1703–1713 (2010).
   PubMed Web of Science ®Google Scholar
• Baldelli S , MerliniS , PericoNet al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics8(9), 1127–1141 (2007).
   PubMed Web of Science ®Google Scholar
• Ruschel LR , SchmittVM , SilvaABet al. Study on the association of UGT1A9 gene c.98T >C polymorphism and mycophenolic acid plasma levels in renal transplant patients. Genet. Mol. Res.16(2), gmr16029598 (2017).
   Google Scholar
• Filler G , Alvarez-EliasAC , McIntyreC , MedeirosM. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy. Pediatr. Nephrol.32(1), 21–29 (2017).
   PubMed Web of Science ®Google Scholar
• Mazidi T , RouiniMR , GhahremaniMHet al. Impact of UGT1A9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients. Iran. J. Pharm. Res.12(3), 547–556 (2013).
   PubMed Web of Science ®Google Scholar
• Sanchez-Fructuoso AI , MaestroML , CalvoNet al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant. Proc.41(6), 2313–2316 (2009).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , de JongeH , NaesensMet al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin. Ther.30(4), 673–683 (2008).
   PubMed Web of Science ®Google Scholar
• Ciliao HL , Camargo-GodoyR , SouzaMF , ZanutoA , DelfinoV , ColusI. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil. Mutat. Res. Genet. Toxicol. Environ. Mutagen836(Pt B), 97–102 (2018).
   PubMedGoogle Scholar
• Billing H , HockerB , FichtnerAet al. Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: a pharmacogenetic substudy of the TWIST trial. Ther. Drug Monit.39(1), 21–28 (2017).
   PubMed Web of Science ®Google Scholar
• Ciliao HL , Camargo-GodoyR , de SouzaMFet al. Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients. J. Toxicol. Environ. Health A80(13–15), 661–671 (2017).
   PubMed Web of Science ®Google Scholar
• Girard H , CourtMH , BernardOet al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics14(8), 501–515 (2004).
   PubMedGoogle Scholar
• Fukuda T , GoebelJ , CoxSet al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther. Drug Monit.34(6), 671–679 (2012).
   PubMed Web of Science ®Google Scholar
• Girard H , VilleneuveL , CourtMHet al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos.34(7), 1220–1228 (2006).
   PubMed Web of Science ®Google Scholar
• Ciftci HS , DemirE , KaradenizMSet al. Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant. Ren. Fail.40(1), 395–402 (2018).
   PubMed Web of Science ®Google Scholar
• Inoue K , MiuraM , SatohSet al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther. Drug Monit.29(3), 299–304 (2007).
   PubMed Web of Science ®Google Scholar
• Kagaya H , NiiokaT , SaitoMet al. Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. Xenobiotica47(10), 916–922 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang WX , ChenB , JinZet al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica38(11), 1422–1436 (2008).
   PubMed Web of Science ®Google Scholar
• Yamanaka H , NakajimaM , KatohMet al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics14(5), 329–332 (2004).
   PubMedGoogle Scholar
• Xiao C , SunH , DengG , SongG. Effect of SNP rs10187694 of UGT1A10 gene on metabolism of mycophenolate mofetil. Chin. J. Mod. Med.27(12), 9–14 (2017).
   Google Scholar
• Pithukpakorn M , TiwawanwongT , LalerdYet al. Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. Pharmgenomics Pers. Med.7, 379–385 (2014).
   PubMedGoogle Scholar
• Djebli N , PicardN , RerolleJP , LeMeur Y , MarquetP. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet. Genomics17(5), 321–330 (2007).
   PubMed Web of Science ®Google Scholar
• van Agteren M , ArmstrongVW , van SchaikRHet al. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G >A gene polymorphism. Ther. Drug Monit.30(4), 439–444 (2008).
   PubMed Web of Science ®Google Scholar
• Song G , DengG , WangYet al. Effect of SNP rs7439366 in UGT2B7 on MMF metabolism. J. Med. Res.44(11), 22–25 (2015).
   Google Scholar
• Pazik J , OldakM , LewandowskiZet al. Uridine diphosphate glucuronosyltransferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection. Transplant. Proc.45(4), 1516–1519 (2013).
   PubMed Web of Science ®Google Scholar
• Yang JW , LeePH , HutchinsonIV , PravicaV , ShahT , MinDI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther. Drug Monit.31(5), 542–548 (2009).
   PubMed Web of Science ®Google Scholar
• Duguay Y , BaarC , SkorpenF , GuillemetteC. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther.75(3), 223–233 (2004).
   PubMed Web of Science ®Google Scholar
• Yu ZC , ZhouPJ , WangXHet al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta Pharmacol. Sin.38(11), 1566–1579 (2017).
   PubMed Web of Science ®Google Scholar
• Dupuis R , YuenA , InnocentiF. The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Clin. Chim. Acta413(17–18), 1318–1325 (2012).
   PubMed Web of Science ®Google Scholar
• Hesselink DA , van GelderT. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin. Pharmacol. Ther.78(4), 317–321 (2005).
   PubMed Web of Science ®Google Scholar
• Satoh S , TadaH , MurakamiMet al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation82(4), 486–493 (2006).
   PubMed Web of Science ®Google Scholar
• Genvigir F , NishikawaAM , FelipeCRet al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in Brazilian kidney transplant recipients. Pharmacotherapy37(5), 535–545 (2017).
   PubMed Web of Science ®Google Scholar
• Varnell CD , FukudaT , KirbyCLet al. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: influence of genes and drugs. Pediatr. Transplant.21(7), e13033 (2017).
   Web of Science ®Google Scholar
• Levesque E , Benoit-BiancamanoMO , DelageR , CoutureF , GuillemetteC. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics9(7), 869–879 (2008).
   PubMed Web of Science ®Google Scholar
• Bosma PJ , ChowdhuryJR , BakkerCet al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl. J. Med.333(18), 1171–1175 (1995).
   PubMed Web of Science ®Google Scholar
• Evans WE , McLeodHL. Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348(6), 538–549 (2003).
   PubMed Web of Science ®Google Scholar